Continuous Renal Replacement Therapy Without Anticoagulation: Top Ten Tips to Prevent Clotting

2020 ◽  
Vol 49 (4) ◽  
pp. 490-495
Author(s):  
Ian Baldwin ◽  
Daryl Jones ◽  
Paula Carty ◽  
Nigel Fealy

Continuous renal replacement therapy (CRRT) is intended to function continuously and is prescribed for this outcome. Anticoagulants may not always be used. Clotting and clogging within the CRRT filter stopping therapy occurs with a variability in the total elapsed time associated. This is commonly known as the circuit or filter “life”. It is very useful and important to record this time at the bedside and refer to this as a measure of success and quality. Filter life (i.e., hours) is reported in many reports investigating CRRT but is not well understood or clear for when this is considered inadequate and clinical review strategies should be considered. Failure before 8 h could be associated with inadequate renal support and “therapy”. Anticoagulation is the key intervention to prolong filter function; however, the extracorporeal circuit design and set up, access catheter profile and insertion site, CRRT machine settings, and the human interface operating CRRT are always important and the only consideration to prevent failure when no anticoagulation is mandated for CRRT.

Critical Care ◽  
2014 ◽  
Vol 18 (4) ◽  
pp. R161 ◽  
Author(s):  
Yi Wang ◽  
Terry P Haines ◽  
Paul Ritchie ◽  
Craig Walker ◽  
Teri A Ansell ◽  
...  

2021 ◽  
pp. 039139882110312
Author(s):  
Vivek Gupta ◽  
Naved Aslam ◽  
Shibba Takkar Chhabra ◽  
Vikas Makkar ◽  
Bishav Mohan ◽  
...  

Objective: The objective of this study was to investigate the impact of anti-platelet drug/s on duration of continuous renal replacement therapy (CRRT) in those patients where anti-coagulants were not used due to certain contraindications and in cases where patients were on anti-platelet drugs and were given anti-coagulant during CRRT. Method: This single-center, retrospective cohort study was conducted using the medical records patients treated with CRRT in the cardiac ICU of the inpatient urban facility, located in North India. Data was collected from only those patients who received CRRT for the duration of at least 12 h. Patient’s in NAC group were not on any anti-platelet/s and did not receive anti-coagulant during CRRT. AC and AP group patients received anti-coagulant alone or were already on anti-platelet/s and did not receive anti-coagulant respectively while ACAP group patients were on anti-platelet drug/s and also received anti-coagulant during CRRT. Result: Patients in AC, AP, or ACAP group showed significantly ( p < 0.001) higher CRRT filter life compared to NAC group. The median CRRT filter life was significantly higher in the ACAP group compared to AC ( p < 0.05) and AP ( p < 0.001) groups. Conclusion: This study indicates that systemic anti-platelet therapy can provide additional support in critical patients undergoing CRRT even with or without anti-coagulant therapy. However, the increase in CRRT filter life was more profound in patients who were on anti-platelet/s and also received anti-coagulant drug/s during CRRT.


2021 ◽  
Vol 9 (2) ◽  
pp. 159-162
Author(s):  
Younes Oujidi ◽  
Imane Melhaoui ◽  
Layla Kherroubi ◽  
Houssam Bkiyar ◽  
Brahim Housni

Introduction: Extracorporeal membrane oxygenation (ECMO) is a therapy that ameliorate the oxygenation of hypoxemia refractory patient it could be associated to a kidney failure that necessity a Continuous Renal Replacement Therapy. Case Report: We report the case of a 68-year-old patient, who presents ARDS due to covid infection, during his hospitalisation the patient presented a refractory hypoxemia with the need to set up ECMO, the case worsened with kidney failure with need for CRRT. Conclusion: The association between ECMO and CRRT might be a safe and effective technique. A variety of ECMO and CRRT combination methods can be chosen, this remains an association that should be investigated in order to improve the prognosis of kidney failure on ECMO.


2019 ◽  
Vol 47 (3) ◽  
pp. 281-287 ◽  
Author(s):  
Chathuri U Dissanayake ◽  
Chrianna I Bharat ◽  
Brigit L Roberts ◽  
Matthew HR Anstey

We compared the cost of continuous renal replacement therapy (CRRT) in critically ill patients using two different anticoagulation strategies: regional citrate and low-dose systemic heparin in a single-centre, prospective observational study in an adult Australian tertiary intensive care unit (ICU). All patients receiving CRRT between October 2015 and May 2016 were included in the study. Costs were modelled using the number of filter sets, number of dialysis bags, amount of citrate, heparin and calcium replacement required, and cost of monitoring the anticoagulation. The primary outcome was cost associated with CRRT per patient per day. The secondary outcome was efficacy of CRRT. In total, 66 patients were commenced on dialysis that required anticoagulation. Twenty-four patients were commenced on regional citrate anticoagulation and 42 patients commenced on systemic low-dose heparin anticoagulation. Median filter life, though not statistically significant, was longer in the citrate group by 7.7 hours ( P=0.152), however the median cost of anticoagulation was AUD$317.91 higher in the citrate than the heparin group per patient per day ( P=0.0020). While regional citrate anticoagulation may prolong filter life, it is also more expensive than low-dose systemic heparin. Choice of anticoagulation in CRRT should include cost as one of the variables that clinicians consider.


Sign in / Sign up

Export Citation Format

Share Document